Viking Therapeutics (VKTX) Misses Q4 EPS by 12c

Viking Therapeutics (NASDAQ: VKTX) reported Q4 EPS of ($0.56), $0.12 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Keefe, Bruyette & Woods Downgrades Crescent BDC (CCAP) to Market Perform
• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight